Compare FIP & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIP | FBRX |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | United States |
| Employees | 1110 | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.1M | 487.2M |
| IPO Year | 2021 | 2017 |
| Metric | FIP | FBRX |
|---|---|---|
| Price | $4.53 | $21.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $11.00 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 1.2M | 193.6K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | 16.91 | ★ 61.30 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $502,520,000.00 | $36,000.00 |
| Revenue This Year | $58.19 | N/A |
| Revenue Next Year | $30.58 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 51.59 | N/A |
| 52 Week Low | $3.90 | $7.78 |
| 52 Week High | $7.93 | $35.80 |
| Indicator | FIP | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 38.19 |
| Support Level | $4.53 | $10.38 |
| Resistance Level | $6.28 | $22.61 |
| Average True Range (ATR) | 0.36 | 2.15 |
| MACD | -0.05 | -0.41 |
| Stochastic Oscillator | 25.49 | 24.86 |
FTAI Infrastructure Inc is engaged in five segments; Railroad segment, which includes eight freight railroads and one switching company that provide rail service to certain manufacturing and production facilities; the Jefferson Terminal segment, which consists of a multi-modal crude oil and refined products terminal and other related assets; The Repauno segment, which consists of a deep-water port located along the Delaware River with an underground storage cavern, a multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities; Power and Gas segment, which comprised Long Ridge, a multi-modal terminal located along the Ohio River; and Sustainability and Energy Transition segment, which comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.